Gene Expression Sample Clauses

Gene Expression. Genetic and pharmacological mechanisms to control gene expression will be presented, including antisense oligonucleotides, inhibitory RNAs (e.g. short-hairpin RNA) and microRNA.
AutoNDA by SimpleDocs
Gene Expression. Following identification of the entire novel gene sequence, gene expression is determined in a number of tissues including brain, liver, pancreas, and muscle. In addition, gene expression under a variety of metabolic disturbances including obesity, fasting, aver-feeding and diabetes is determined. The pattern o£ gene expression is then examined to identify leads for future experiments aimed at identifying the function of the novel gene. A major advance in technology in the area of gene expression is ‘real-time PCR’ which is now routinely available in our laboratory and allows accurate and rapid determination of gene expression. Following detailed animal experiments in Psammomys obesus and to confirm the importance of the identified gene in human metabolism, human RNA blots are used to examine gene expression in a variety of human tissues.
Gene Expression. Gene expression is the process of using a gene’s information in the synthesis of a functional gene product (usually a protein). Gene expression is the most fundamental level in genetics since the genotype gives rise to the phenotype through gene expression. By the definition of gene expression, the amount of functional gene products (usually proteins) should be measured. However, the measurement for functional gene products is difficult and often the abundance of messenger RNA (mRNA), an intermediate product positively correlated with functional gene product, is measured to determine the intensity for gene expression. Gene expression microarray and RNA-Seq are actually two different methods measuring the intensity of mRNA. Gene expression microarray uses an “array”, a collection of microscopic DNA spots attached to a solid surface, to hybridize cDNAs (converted from mRNAs) for target genes. On the other hand, RNA-Seq sequences cDNA and all the sequence fragments (Reads) will be aligned to a reference genome to reflect the intensity of gene expression. Preprocessing and normalization are extremely important topics for both microarray and RNA-Seq data (Ghosh & Qin, 2010). In this dissertation, we skip the preprocessing and normalization steps and focus on the downstream analyses, assuming our data have already been properly preprocessed and normalized. After appropriate preprocessing and normalization, microarray data can be summarized into an I by K matrix that stores log transformed gene expression levels across I genes and K samples. An important task of analyzing gene expression data from different conditions is to identify DE genes in an experiment that compares two groups (conditions) of samples. We define the two groups as the control group and the treatment group. Let Xijk denotes the normalized log expression value, where i denotes different genes, j denotes different conditions (control group or treatment group), k denotes different replicates. i = 1, 2…I, j = 1, 2. k = 1, 2….n. The basic assumption for the log gene expression value is: (1) where , denotes the mean for the ith gene in the jth group and 2 is the variance for the ith gene. We test whether the mean expression for a certain gene is significantly different between the two groups. For the ith gene, the hypotheses are: H0: ,1 = ,2 versus HA: ,1 ≠ ,2. A natural statistical tool for detecting DE genes is to apply the two sample Student's t-test to each gene and calculate the t statistics: =...
Gene Expression. ‌ The transcriptome maps presented revealed localised differences in the expres- sion levels between different tissues and different developmental stages. These differences were shown to follow certain trends at the level of isochores, as discussed in the previous section. In order to attribute the differences at the isochore level to differences at the gene level, the expression data was mapped onto the NCBI Consensus Coding Sequence Database (CCDS) and normalised for the length of each coding sequence (CDS) and the total number of reads mapped onto the coding sequences of the tissue (Equation 3.4). Figure 3.5 demonstrates that the normalised expression of genes, averaged per isochore, follows similar patterns as those shown for the expression at isochore level, after the gene density was factored out (Fig. 3.4), albeit the correlations are consid- erably weaker. Here again, despite the adult tissues’ showing a positive correlation between the gene expression and the GC content of the isochores, the gene expression during development appears to be independent of the base composition of the isochores, with genes in GC-poor isochores matching in expression level the genes in GC-rich isochores. Therefore the positive correlation between the ex- pression level and the GC content observed in the adult tissues is the result of differential regulation of genes in GC-poor and GC-rich isochores, possibly at the level of entire isochores, as discussed previously.
Gene Expression. Clones isolated from the fed flea gut cDNA expression library will be expressed in E. coil and the resulting fusion proteins characterized by Western blot analysis with immune sera. To verify that the recombinant clones encode the protein of interest, fusion protein expressed by the purified recombinant phage is bound to a nitrocellulose filter and used to affinity-purify clone- specific Antibodies from the
Gene Expression. Clones isolated from the fed flea gut cDNA expression library will be expressed in E. coli and the resulting fusion proteins characterized by Western blot analysis with immune sera. To verify that the recombinant clones encode the protein of interest, fusion protein expressed by the purified recombinant phage is bound to a nitrocellulose filter and used to affinity-purify clone- specific antibodies from the original immune sera. The monospecific antibodies are then eluted and used in Western blot analysis to identify the molecular weight of the native flea gut antigen encoded by the recombinant. The clones will be subcloned into a vector system optimized for large scale production of fusion protein that can be purified by affinity chromotography.

Related to Gene Expression

  • Final Expression This Agreement is the final expression of the terms and conditions of this VISA line of credit between you and Credit Union. This written Agreement may not be contradicted by evidence of any alleged oral agreement.

  • Defined expressions Words and expressions defined in the Loan Agreement and the other Finance Documents shall have the same meanings when used in this Agreement unless the context otherwise requires.

  • Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.

  • Background Screening and Security ‌ All Contractor employees and agents performing work under the Contract must comply with all security and other requirements of the Department.

  • PROGENY Unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or organism from organism.

  • Definitions and Scope 1.1 Employees shall have the right to present grievances in accordance with the procedures prescribed in this Article. 1.2 For purposes of this Agreement, a grievance is a dispute concerning the interpretation or application of the terms or provisions of this Agreement. It is intended that this shall not mean administrative matters under the Retirement System and the Group Health Insurance Program.

  • Plurals and Gender Where appearing in this Agreement the singular shall include the plural and the masculine shall include the feminine, and vice versa, unless the context clearly indicates a different meaning.

  • Recitals and Exhibits The foregoing recitals and any attached exhibits are material to this Agreement and are incorporated into and made a part of this Agreement.

  • Singular Includes the Plural; Gender; Title Reference Whenever the singular number is used in this Contract and when required by the context, the same shall include the plural, and the use of any gender, be it masculine, feminine or neuter, shall include all of the genders, and the word “person” or “entity” shall include corporation, firm, partnership, or any other combination or association. The use of the title “Bidder”, “Vendor”, “Contractor” or “Consultant” within this contract or associated bid documents shall be deemed interchangeable and shall refer to the person or entity with whom the City of Sparks is contracting for the service or product referenced within this contract.

  • Product References a. “Or Equal” In all Solicitations or Bid Specifications, the words “or equal” are understood to apply where a copyrighted, brand name, trade name, catalog reference, or patented Product is referenced. References to such specific Product are intended as descriptive, not restrictive, unless otherwise stated. Comparable Product will be considered if proof of compatibility is provided, including appropriate catalog excerpts, descriptive literature, specifications and test data, etc. The Commissioner’s decision as to acceptance of the Product as equal shall be final. b. Discrepancies in References In the event of a discrepancy between the model number referenced in the Solicitation or Bid Specifications and the written description of the Products that cannot be reconciled, then the written description shall prevail.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!